Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of RBP-7000 with different polymer weights in schizophrenia
NCT02687984Phase 1Completed
- Sponsor
- Indivior
- Start
- Feb 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risperidone in schizophrenia (3 arms), sponsored by Indivior. Primary endpoints: Maximum Plasma Concentration of Risperidone and Area Under the Plasma Concentration-Time Curve of Risperidone. Started Feb 2016; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02687984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687984.